Apexia Bio

Our flagship minimal viable product, MYscore24, is a patent-pending, cost-effective, scalable and non-invasive blood-based test predictive of survival and disease progression in myelofibrosis patients. Myelofibrosis is a rare, chronic, stem-cell based blood cancer with low probability of survival and high risk of disease progression to acute leukemia.